File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/YCO.0b013e32834a3f47
- Scopus: eid_2-s2.0-80053386363
- PMID: 21799414
- WOS: WOS:000295321400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Recent advances in pharmacological treatment of psychosis in late life
Title | Recent advances in pharmacological treatment of psychosis in late life |
---|---|
Authors | |
Issue Date | 2011 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-psychiatry.com |
Citation | Current Opinion In Psychiatry, 2011, v. 24 n. 6, p. 455-460 How to Cite? |
Abstract | Purpose of review: Psychosis is among the most frequent psychiatric symptoms in late life. Treatment of late life psychosis is often challenging because of age-related changes, physical comorbidities and frailty of older adults. The present study aims at reviewing recent literature on pharmacological treatment of psychosis in the older population. RECENT FINDINGS: Recent studies show that antipsychotics remain the mainstay of treatment for older adults with psychosis. Although the efficacies of both typical and atypical antipsychotics have been demonstrated in older adults with schizophrenia, delirium and Parkinson's disease psychosis, there is a growing body of data favoring atypical antipsychotics. However, most of the evidence is not based on rigorously conducted trials. In addition, the use of antipsychotic medication in managing psychosis associated with dementia has declined significantly with the recognition of its serious adverse effects in this vulnerable population. A recent study suggests that effective alternative treatments are yet to be developed. SUMMARY: Studies have demonstrated the clinical benefits of antipsychotics in older people with psychosis. The potential benefits from the use of antipsychotics must be weighed against their adverse effects. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. |
Persistent Identifier | http://hdl.handle.net/10722/171969 |
ISSN | 2023 Impact Factor: 7.5 2023 SCImago Journal Rankings: 2.333 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, WC | en_HK |
dc.contributor.author | Lam, LCW | en_HK |
dc.contributor.author | Chen, EYH | en_HK |
dc.date.accessioned | 2012-10-30T06:19:00Z | - |
dc.date.available | 2012-10-30T06:19:00Z | - |
dc.date.issued | 2011 | en_HK |
dc.identifier.citation | Current Opinion In Psychiatry, 2011, v. 24 n. 6, p. 455-460 | en_HK |
dc.identifier.issn | 0951-7367 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/171969 | - |
dc.description.abstract | Purpose of review: Psychosis is among the most frequent psychiatric symptoms in late life. Treatment of late life psychosis is often challenging because of age-related changes, physical comorbidities and frailty of older adults. The present study aims at reviewing recent literature on pharmacological treatment of psychosis in the older population. RECENT FINDINGS: Recent studies show that antipsychotics remain the mainstay of treatment for older adults with psychosis. Although the efficacies of both typical and atypical antipsychotics have been demonstrated in older adults with schizophrenia, delirium and Parkinson's disease psychosis, there is a growing body of data favoring atypical antipsychotics. However, most of the evidence is not based on rigorously conducted trials. In addition, the use of antipsychotic medication in managing psychosis associated with dementia has declined significantly with the recognition of its serious adverse effects in this vulnerable population. A recent study suggests that effective alternative treatments are yet to be developed. SUMMARY: Studies have demonstrated the clinical benefits of antipsychotics in older people with psychosis. The potential benefits from the use of antipsychotics must be weighed against their adverse effects. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. | en_HK |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-psychiatry.com | en_HK |
dc.relation.ispartof | Current Opinion in Psychiatry | en_HK |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Antipsychotic Agents - Therapeutic Use | en_US |
dc.subject.mesh | Delirium - Psychology | en_US |
dc.subject.mesh | Dementia - Psychology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Parkinson Disease - Psychology | en_US |
dc.subject.mesh | Psychotic Disorders - Drug Therapy | en_US |
dc.subject.mesh | Schizophrenia - Drug Therapy | en_US |
dc.title | Recent advances in pharmacological treatment of psychosis in late life | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Chan, WC: waicchan@hku.hk | en_HK |
dc.identifier.email | Chen, EYH: eyhchen@hku.hk | en_HK |
dc.identifier.authority | Chan, WC=rp01687 | en_HK |
dc.identifier.authority | Chen, EYH=rp00392 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1097/YCO.0b013e32834a3f47 | en_HK |
dc.identifier.pmid | 21799414 | - |
dc.identifier.scopus | eid_2-s2.0-80053386363 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-80053386363&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 24 | en_HK |
dc.identifier.issue | 6 | en_HK |
dc.identifier.spage | 455 | en_HK |
dc.identifier.epage | 460 | en_HK |
dc.identifier.isi | WOS:000295321400001 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Chan, WC=16400525900 | en_HK |
dc.identifier.scopusauthorid | Lam, LCW=7201984627 | en_HK |
dc.identifier.scopusauthorid | Chen, EYH=7402315729 | en_HK |
dc.identifier.issnl | 0951-7367 | - |